| Index | — | P/E | 13.93 | EPS (ttm) | 3.57 | Insider Own | 2.09% | Shs Outstand | 47.37M | Perf Week | 3.28% |
| Market Cap | 2.36B | Forward P/E | 9.69 | EPS next Y | 5.13 | Insider Trans | -0.22% | Shs Float | 46.70M | Perf Month | 9.88% |
| Enterprise Value | 4.32B | PEG | 2.11 | EPS next Q | 1.07 | Short Float | 8.49% | Perf Quarter | -4.37% | ||
| Income | 172.00M | P/S | 2.13 | EPS this Y | 0.97% | Short Ratio | 7.12 | Perf Half Y | -10.09% | ||
| Sales | 1.10B | P/B | 1.23 | EPS next Y | 11.95% | ROA | 3.77% | Short Interest | 3.96M | Perf YTD | -19.39% |
| Book/sh | 40.46 | P/C | 26.47 | EPS next 5Y | 6.60% | ROE | 9.22% | 52W High | 71.07 -30.03% | Perf Year | -17.49% |
| Cash/sh | 1.88 | P/FCF | 10.03 | EPS past 3/5Y | — 3.77% | ROIC | 4.80% | 52W Low | 42.62 16.68% | Perf 3Y | -16.64% |
| Dividend Est. | — | EV/EBITDA | 13.80 | Sales past 3/5Y | -1.17% 2.92% | Gross Margin | 53.26% | Volatility | 2.84% 2.85% | Perf 5Y | -16.98% |
| Dividend TTM | — | EV/Sales | 3.91 | EPS Y/Y TTM | -16.20% | Oper. Margin | 26.26% | ATR (14) | 1.48 | Perf 10Y | 4.52% |
| Dividend Ex-Date | Sep 27, 2018 | Quick Ratio | 1.99 | Sales Y/Y TTM | -1.43% | Profit Margin | 15.57% | RSI (14) | 57.11 | Recom | 2.47 |
| Dividend Gr. 3/5Y | — 8.73% | Current Ratio | 3.23 | EPS Q/Q | 3.16% | SMA20 | 2.51% | Beta | 0.29 | Target Price | 81.67 |
| Payout | 0.00% | Debt/Eq | 1.07 | Sales Q/Q | 6.40% | SMA50 | 2.54% | Rel Volume | 1.08 | Prev Close | 49.06 |
| Employees | 890 | LT Debt/Eq | 1.07 | Earnings | Nov 05 | SMA200 | -7.92% | Avg Volume | 551.62K | Price | 49.73 |
| IPO Date | Feb 10, 2005 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.64% 5.01% | Net Debt/EBITDA | 6.27 | Volume | 596,079 | Change | 1.37% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-14-26 | Downgrade | Oppenheimer | Outperform → Perform | |
| Oct-27-25 | Reiterated | Jefferies | Hold | $71 |
| Nov-05-24 | Reiterated | Canaccord Genuity | Buy | $71 → $86 |
| Jun-21-24 | Upgrade | DA Davidson | Neutral → Buy | $93 |
| Nov-17-22 | Reiterated | Canaccord Genuity | Buy | $71 |
| May-10-22 | Upgrade | Jefferies | Hold → Buy | |
| May-09-22 | Upgrade | Oppenheimer | Perform → Outperform | |
| Aug-07-20 | Downgrade | DA Davidson | Buy → Neutral | |
| Mar-26-20 | Upgrade | Jefferies | Hold → Buy | |
| Mar-19-20 | Upgrade | DA Davidson | Neutral → Buy |
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,105 | 1,089 | 1,138 | 1,125 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 517 | 514 | 503 | 501 | — | — | — | — | — | |
| Gross Profit | 588 | 575 | 634 | 624 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 280 | 265 | 264 | 259 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 18 | 0 | 34 | 23 | — | — | — | — | — | |
| Operating Income | 290 | 309 | 337 | 342 | — | — | — | — | — | |
| Interest Expense | 46 | 42 | 48 | 67 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10 | -10 | -5 | 1 | — | — | — | — | — | |
| Net Income Before Taxes | 235 | 257 | 284 | 276 | — | — | — | — | — | |
| Income Taxes | 62 | 67 | 70 | 67 | — | — | — | — | — | |
| Consolidated Net Income | 172 | 190 | 215 | 209 | — | — | — | — | — | |
| Net Income From Continuing Operations | 172 | 190 | 215 | 209 | — | — | — | — | — | |
| Net Income | 172 | 190 | 215 | 209 | — | — | — | — | — | |
| EPS (Recurring) | 3.59 | 3.93 | 4.32 | 4.21 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.59 | 3.93 | 4.32 | 4.21 | — | — | — | — | — | |
| EPS (Diluted) | 3.57 | 3.91 | 4.29 | 4.17 | — | — | — | — | — | |
| EBITDA | 313 | 331 | 362 | 374 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 13.93 | 15.16 | 20.04 | 17.40 | — | — | — | — | — | |
| Price To Sales Ratio | 2.12 | 2.61 | 3.78 | 3.22 | — | — | — | — | — | |
| Gross Margin | 53.21 | 52.80 | 55.71 | 55.47 | — | — | — | — | — | |
| Operating Margin | 26.24 | 28.37 | 29.61 | 30.40 | — | — | — | — | — | |
| Net Margin | 15.57 | 17.45 | 18.89 | 18.58 | — | — | — | — | — | |
| Shares Outstanding | 47 | 48 | 50 | 50 | — | — | — | — | — | |
| Market Capitalization | 2,337 | 2,845 | 4,299 | 3,628 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zerillo Jeffrey | Senior VP Operations | May 11 '26 | Sale | 52.28 | 351 | 18,350 | 41,810 | May 12 |
| Zerillo Jeffrey | Senior VP Operations | May 07 '26 | Sale | 54.36 | 305 | 16,580 | 42,161 | May 11 |
| Zerillo Jeffrey | Senior VP Operations | May 05 '26 | Sale | 55.06 | 1,553 | 85,514 | 42,820 | May 07 |
| Zerillo Jeffrey | Senior VP Operations | Feb 11 '26 | Sale | 65.93 | 1,000 | 65,930 | 41,048 | Feb 13 |
| Zerillo Jeffrey | Senior VP Operations | Dec 01 '25 | Sale | 60.00 | 281 | 16,860 | 42,048 | Dec 02 |
| Zerillo Jeffrey | Senior VP Operations | Nov 28 '25 | Sale | 60.00 | 719 | 43,140 | 42,329 | Dec 02 |
| BYOM JOHN E | Director | Nov 25 '25 | Sale | 59.35 | 3,000 | 178,050 | 51,594 | Nov 26 |
| Fritz Mary Beth | SVP Quality & Regulatory | Mar 10 '25 | Sale | 90.00 | 1,678 | 151,020 | 17,157 | Mar 12 |
| Fritz Mary Beth | SVP Quality & Regulatory | Mar 03 '25 | Option Exercise | 44.33 | 6,297 | 279,146 | 25,132 | Mar 05 |
| Fritz Mary Beth | SVP Quality & Regulatory | Mar 03 '25 | Sale | 85.39 | 6,297 | 537,701 | 18,835 | Mar 05 |
| Mekhail Adel | EVP, Marketing & Sales | Feb 11 '25 | Option Exercise | 49.53 | 11,083 | 548,935 | 24,048 | Feb 13 |
| Mekhail Adel | EVP, Marketing & Sales | Feb 11 '25 | Sale | 86.55 | 11,083 | 959,271 | 18,365 | Feb 13 |
| Lombardi Ronald M. | Chief Executive Officer | Nov 19 '24 | Option Exercise | 56.62 | 10,875 | 615,774 | 326,614 | Nov 21 |
| Lombardi Ronald M. | Chief Executive Officer | Nov 19 '24 | Sale | 82.60 | 10,875 | 898,241 | 320,952 | Nov 21 |
| Lombardi Ronald M. | Chief Executive Officer | Nov 18 '24 | Option Exercise | 56.74 | 82,237 | 4,666,226 | 369,464 | Nov 19 |